World Pharma News

Syndicate content
World Pharma News - one of the world's leading web-based pharmaceutical news publications - is committed to providing and disseminating the most prominent pharmaceutical news and achievements
Updated: 1 hour 29 min ago

AMJEVITA™ (adalimumab-atto), first biosimilar to Humira® now available in the United States

Tue, 01/31/2023 - 11:00
Amgen (NASDAQ:AMGN) today announced AMJEVITA™ (adalimumab-atto), a biosimilar to Humira®* (adalimumab), is now available in the United States. AMJEVITA was the first biosimilar to Humira approved by the U.S. Food and Drug Administration (FDA), in 2016.(1,2)

CHMP recommends Bayer’s darolutamide for the treatment of metastatic hormone-sensitive prostate cancer

Mon, 01/30/2023 - 11:00
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended darolutamide, an oral androgen receptor inhibitor (ARi), plus ADT in combination with docetaxel for marketing authorization in the European Union (EU) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC).

Keys to making immunotherapy work against pancreatic cancer found in tumor microenvironment

Fri, 01/27/2023 - 13:00
A new study that analyzed the tumor microenvironment of pancreatic cancer revealed the cause of tumor cell resistance to immunotherapy and resulted in new treatment strategies.

This study, led by researchers at the Johns Hopkins Kimmel Cancer Center, is the latest from an ongoing platform trial formed in 2015 to study immunotherapy treatments before surgery (neoadjuvant) and after surgery (adjuvant) in patients with pancreatic cancer.

SAE Media Group proudly presents the 4th Annual AI in Drug Discovery Conference

Fri, 01/27/2023 - 11:00
13 - 14 March 2023, London, UK.
SAE Media Group is proud to present its 4th Annual AI in Drug Discovery Conference, taking place from 13 - 14 March 2023 in London, UK.

With the recent pandemic highlighting the need for rapid drug discovery, AI has become an area of increased interest. This is driven by the ability to discover drugs through the use of machine and deep learning.

Discovery of anti-cancer chemistry makes skullcap fit for modern medicine

Thu, 01/26/2023 - 11:00
The evolutionary secrets that enable the medicinal herb known as barbed skullcap to produce cancer fighting compounds have been unlocked by a collaboration of UK and Chinese researchers.

The CEPAMS collaboration used DNA sequencing technology to assemble the genomic sequence of skullcap (Scutellaria barbata) known in China as banzhilian.

Coordination of COVID-19 vaccine clinical trials produces a 'treasure trove' of data and a model for the future

Wed, 01/25/2023 - 11:00
The federally funded COVID-19 Prevention Network (CoVPN), headquartered at Fred Hutchinson Cancer Center in Seattle, was instrumental in the rapid development of safe, effective and lifesaving COVID-19 vaccines during earlier phases of the pandemic.

Its vital work to expedite Phase 3 COVID-19 vaccine clinical trials also resulted in a highly collaborative and harmonized approach that can serve as a national and even international model for major research initiatives while also guiding responses to future public health emergencies.

Power of cancer drugs may see boost by targeting newly ID'd pathway

Tue, 01/24/2023 - 11:00
Cells zealously protect the integrity of their genomes, because damage can lead to cancer or cell death. The genome - a cell's complete set of DNA - is most vulnerable while it is being duplicated before a cell divides. Cancer cells constantly are dividing, so their genomes are constantly in jeopardy.

Researchers at Washington University School of Medicine in St. Louis have identified a previously unknown signaling pathway cells use to protect their DNA while it is being copied.

A soybean protein blocks LDL cholesterol production, reducing risks of metabolic diseases

Mon, 01/23/2023 - 11:00
A protein in soybeans blocks the production of a liver enzyme involved in the metabolism of triglycerides and low-density lipoprotein, scientists found in a recent study.

Consuming soy flour rich in the protein B-conglycinin has the potential to reduce LDL cholesterol levels and lower the risk of metabolic diseases such as atherosclerosis and fatty liver disease,

Roche announces the European Commission approval of Xofluza for the treatment and prevention of influenza in children aged one year and above

Fri, 01/20/2023 - 11:00
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the European Commission (EC) has approved Xofluza® (baloxavir marboxil) in children aged one year and above for the treatment of uncomplicated influenza and for post-exposure prophylaxis of influenza. Post-exposure prophylaxis aims to prevent influenza in individuals following contact with someone infected with the influenza virus.

500,000 missed out on blood pressure lowering drugs during pandemic

Thu, 01/19/2023 - 11:00
Nearly half a million people missed out on starting medication to lower their blood pressure during the COVID-19 pandemic, according to research supported by the British Heart Foundation (BHF) Data Science Centre at Health Data Research UK published today in Nature Medicine.

The researchers say that thousands of people could suffer an avoidable heart attack or stroke due to delays in starting these vital medications known to stave-off deadly heart and circulatory diseases.

Pfizer expands 'An Accord for a Healthier World' product offering to include full portfolio for greater benefit to 1.2 billion people in 45 lower-income countries

Wed, 01/18/2023 - 11:00
Pfizer Inc. (NYSE: PFE) announced that it has significantly expanded its commitment to An Accord for a Healthier World to offer the full portfolio of medicines and vaccines for which it has global rights on a not-for-profit basis to enable greater health for 1.2 billion people living in 45 lower-income countries.

Modified CRISPR-based enzymes improve the prospect of inserting entire genes into the genome to overcome diverse disease-causing mutations

Tue, 01/17/2023 - 11:00
Many genetic diseases are caused by diverse mutations spread across an entire gene, and designing genome editing approaches for each patient’s mutation would be impractical and costly.

Investigators at Massachusetts General Hospital (MGH) recently developed an optimized method that improves the accuracy of inserting large DNA segments into a genome.

Acquisition of Neogene Therapeutics completed

Mon, 01/16/2023 - 13:00
AstraZeneca has completed the acquisition of Neogene Therapeutics Inc. (Neogene), a global clinical-stage biotechnology company pioneering the discovery, development and manufacturing of next-generation T-cell receptor therapies (TCR-Ts).

Neogene will operate as a wholly owned subsidiary of AstraZeneca, with operations in Amsterdam, the Netherlands and California, US.

SAE Media Group's 6th annual 3D Cell Culture Conference

Mon, 01/16/2023 - 11:00
8 - 9 February 2023, London, United Kingdom.
SAE Media Group's 6th annual 3D Cell Culture Conference brings together industry experts from big pharma, regulatory bodies, and cutting-edge researchers to discuss the challenges and drivers of these medical technologies, through case studies of the latest innovations in 3D Cell Culture models, real world examples of clinical applications, and insights into regulatory validation and high throughput screening to give a comprehensive look into this fast growing industry.

Study identifies potential new approach for treating lupus

Fri, 01/13/2023 - 11:00
Targeting iron metabolism in immune system cells may offer a new approach for treating systemic lupus erythematosus (SLE) - the most common form of the chronic autoimmune disease lupus.

A multidisciplinary team of investigators at Vanderbilt University Medical Center has discovered that blocking an iron uptake receptor reduces disease pathology and promotes the activity of anti-inflammatory regulatory T cells in a mouse model of SLE.

Bayer to accelerate drug discovery with Google Cloud's high-performance compute power

Thu, 01/12/2023 - 11:00
Bayer AG and Google Cloud announced a collaboration to drive early drug discovery that will apply Google Cloud's Tensor Processing Units (TPUs), which are custom-developed accelerators designed to run cutting-edge machine learning models and computationally-intensive workloads, to help accelerate and scale Bayer's quantum chemistry calculations.

Nanotechnology may improve gene therapy for blindness

Wed, 01/11/2023 - 11:00
Using nanotechnology that enabled mRNA-based COVID-19 vaccines, a new approach to gene therapy may improve how physicians treat inherited forms of blindness.

A collaborative team of researchers with Oregon Health & Science University and Oregon State University have developed an approach that uses lipid nanoparticles - tiny, lab-made balls of fat - to deliver strands of messenger ribonucleic acid, or mRNA, inside the eye.

NextPoint Therapeutics announces $80 million Series B financing co-led by Leaps by Bayer and Sanofi Ventures to advance novel immuno-oncology programs

Tue, 01/10/2023 - 11:00
NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi.

AstraZeneca to acquire CinCor Pharma to strengthen cardiorenal pipeline

Mon, 01/09/2023 - 11:00
AstraZeneca has entered into a definitive agreement to acquire CinCor Pharma, Inc. (CinCor), a US-based clinical-stage biopharmaceutical company, focused on developing novel treatments for resistant and uncontrolled hypertension as well as chronic kidney disease.

FDA grants Accelerated Approval for Alzheimer's disease treatment

Fri, 01/06/2023 - 11:00
Today, the U.S. Food and Drug Administration approved Leqembi (lecanemab-irmb) via the Accelerated Approval pathway for the treatment of Alzheimer's disease. Leqembi is the second of a new category of medications approved for Alzheimer's disease that target the fundamental pathophysiology of the disease. These medications represent an important advancement in the ongoing fight to effectively treat Alzheimer's disease.